

Special Issue

Present and Future Vaccinations: Current Strategies and New Perspectives in the Fight against Infectious Diseases

Message from the Guest Editors

Dear Colleague,

Vaccinations are definitely the most effective preventive tools against infectious diseases, and represent one of the most important achievements in the history of medicine. Most potential new vaccines have an essential composition, sometimes characterized by a low immunogenicity, with the inability to elicit powerful and long-lasting immune responses. Moreover, some considerable infectious diseases, such as HIV, tuberculosis, and malaria, have spread all over the world and are still burdened by a high rate of morbidity and mortality, and are not yet covered by an effective vaccine. Therefore, there is the necessity to obtain modern and effective vaccines, by studying new antigens, adjuvants, and innovative delivery systems that will enhance their immunogenicity.

Implementing the current vaccination strategies and focusing on new technologies to develop the vaccines of the future will certainly be the cornerstone in the everlasting fight against infectious diseases.

Guest Editors

Dr. Alessio Facciola

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98122 Messina, Italy

Dr. Giuseppa Visalli

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98122 Messina, Italy

Deadline for manuscript submissions

closed (31 December 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/71314

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).